Effect of glutathione S-transferases on the survival of patients with acute myeloid leukaemia

European Journal of Pharmacology
Judith L AutrupHerman Autrup

Abstract

The objective of the study was to investigate the effect of genetic polymorphisms in glutathione S-transferases (GST) on the survival of acute myeloid leukaemia patients receiving adriamycin induction therapy. A total of 89 patients were included in the study. Patients who carried at least one GSTM1 allele had trend towards a better survival (mortality rate ratio (RR) 0.588; 95% CI 0.334-1.036) than GSTM1*0/0 patients. However, at low accumulated adriamycin dose, GSTM1*0/0 cases had a better survival than people expressing the gene (RR=6.1; 95% CI=1.2-11.0). The GSTT1 and GSTP1 genotype did not influence the survival in any of the groups.

References

Jun 10, 1998·Toxicology·G PapageorgiouA Dimitriadou-Vafiadou
Oct 23, 1998·Pharmacology & Toxicology·S M DeAtleyD A Butterfield
Jan 22, 2000·European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)·J L AutrupH Autrup
Mar 18, 2000·Toxicology Letters·R C StrangeA A Fryer
Sep 6, 2000·Pharmacology·J D Hayes, R C Strange

❮ Previous
Next ❯

Citations

Sep 7, 2005·Pharmacogenomics·Paola Biason, Giuseppe Toffoli
Feb 11, 2014·Urologic Oncology·Cristián A AcevedoAngela M Roco
Jul 7, 2016·Pharmacogenomics·Juan Eduardo Megías-VericatSalvador F Aliño
Oct 2, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marianne BerwickPaolo Vineis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.